Moriello K A, DeBoer D J
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706, USA.
J Am Vet Med Assoc. 1995 Aug 15;207(4):439-44.
To evaluate the efficacy of itraconazole and griseofulvin in the treatment of Microsporum canis infection, 15 juvenile cats were infected by topical application of 10(5) live M canis macroconidia to the skin of the lateral part of the trunk, and an occlusive bandage was applied. After 3 weeks, cats were randomly assigned to 1 of 3 treatment groups (n = 5 each): cats in the first group received griseofulvin (50 mg/kg of body weight, PO, q 24 h); the second group received itraconazole (10 mg/kg, PO, q 24 h); and the third group (control) received an equivalent volume of vehicle (without drug, PO, q 24 h). Treatment continued for 100 days, or until mycologic cure (lack of dermatophyte isolation on 3 consecutive weekly fungal cultures) was achieved. Infection in all cats peaked in severity at week 6 after inoculation, then gradually resolved over the next 11 weeks. The itraconazole-treated group was the first to achieve a cure, after receiving 56 days of treatment, followed by the griseofulvin-treated group at 70 days. None of the cats in the control group reached mycologic cure after 100 days of treatment. As early as day 14 of treatment, the griseofulvin- and itraconazole-treated groups had significantly (P < 0.05) lower mean infection scores, compared with those in the control group. Significant differences in the mean infection scores between the itraconazole- and griseofulvin-treated groups were not found.(ABSTRACT TRUNCATED AT 250 WORDS)
为评估伊曲康唑和灰黄霉素治疗犬小孢子菌感染的疗效,对15只幼猫进行实验,通过在躯干外侧皮肤局部涂抹10(5)个活的犬小孢子菌大分生孢子进行感染,并使用封闭绷带。3周后,将猫随机分为3个治疗组之一(每组n = 5):第一组猫接受灰黄霉素(50 mg/kg体重,口服,每24小时一次);第二组接受伊曲康唑(10 mg/kg,口服,每24小时一次);第三组(对照组)接受等量的赋形剂(无药物,口服,每24小时一次)。治疗持续100天,或直至实现真菌学治愈(连续3周每周进行真菌培养均未分离到皮肤癣菌)。所有猫的感染在接种后第6周严重程度达到峰值,然后在接下来的11周内逐渐消退。伊曲康唑治疗组在接受56天治疗后第一个实现治愈,其次是灰黄霉素治疗组在70天实现治愈。对照组的猫在治疗100天后均未达到真菌学治愈。早在治疗第14天,与对照组相比,灰黄霉素和伊曲康唑治疗组的平均感染评分显著降低(P < 0.05)。未发现伊曲康唑治疗组和灰黄霉素治疗组之间的平均感染评分有显著差异。(摘要截断于250字)